Product Description
Mechanisms of Action: Epinine Analogue
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: India | Italy | Peru | Portugal
Approved Indications: None
Known Adverse Events: None
Company: John Landers
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Glaucoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ACTRN12611001191987 | P4 |
Completed |
Glaucoma |
2013-07-29 |
|
Predicting Glaucoma Progression | P4 |
Terminated |
Glaucoma |
2011-08-24 |
|
ACTRN12615000767505 | P4 |
Not yet recruiting |
Glaucoma |
None |